2-(N,N-dimethylaminomethyl)-1-ethylpyrrole | 566938-43-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(N,N-dimethylaminomethyl)-1-ethylpyrrole
• 英文别名: 1-(1-Ethyl-1H-pyrrol-2-yl)-N,N-dimethylmethanamine；1-(1-ethylpyrrol-2-yl)-N,N-dimethylmethanamine
• CAS: 566938-43-0
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: JFBHVEAHHRQQJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(N,N-dimethylaminomethyl)-1-ethylpyrrole 、 碘甲烷 以 乙醇 为溶剂， 反应 3.0h， 以66%的产率得到(1-ethylpyrrol-2-yl)methyl trimethylammonium iodide
  参考文献：
  名称：

  EP1733724

  摘要：

  公开号：
• 作为产物：
  描述：

  N-乙吡啶 、 聚合甲醛 、 盐酸二甲胺 在 ice 、 乙醚 、 氯化钠 、 Sodium sulfate-III 、 silica gel 作用下， 以 sodium hydroxide 为溶剂， 反应 7.5h， 以to afford 2-(N,N-dimethylaminomethyl)-1-ethylpyrrole (15.6 g, yield: 97%)的产率得到2-(N,N-dimethylaminomethyl)-1-ethylpyrrole
  参考文献：
  名称：

  Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these

  摘要：

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。

  公开号：

  US20050043386A1

文献信息

• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。
• Amino alcohol compounds or phosphonic acid derivatives thereof
  申请人：Nishi Takahide

  公开号：US20070142335A1

  公开（公告）日：2007-06-21

  A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia): wherein R 1 and R 2 are each a hydrogen, R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or a C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种用于预防或治疗非类风湿性关节炎或牛皮癣等免疫相关疾病的方法，涉及向需要治疗的哺乳动物中投与一种化合物的药物有效量，该化合物的药物学上可接受的盐或酯，其中该化合物具有公式(Ia)：其中R1和R2均为氢，R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C6-C10芳基，或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。
• Amino alcohol compound
  申请人：Nishi Takahide

  公开号：US20070191468A1

  公开（公告）日：2007-08-16

  A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1] (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

  提供了一种低毒性、表现出优越的物理化学性质和药代动力学，并具有优越的外周血淋巴细胞计数降低活性的药物组合物。该药物组合物包含具有一般式（I）的化合物：[化学式1]（其中R1代表甲基基团或乙基基团，R2代表甲基基团或乙基基团，R3代表苯基，该苯基被1至3个取自卤原子、较低烷基基团、环烷基团、较低烷氧基团、卤代较低烷基基团、较低脂肪酰基基团和氰基的取代基所取代），以及其药理学上可接受的盐或药理学上可接受的酯。
• Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
  申请人：Sankyo Company, Limited

  公开号：US07910617B2

  公开（公告）日：2011-03-22

  A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.

  一种抑制外周血淋巴细胞数量的方法，涉及向需要的人体内给予一种药物有效量的化合物，该化合物为（2R）-2-氨基-2-甲基-4-1-甲基-5-[4-(4-甲基苯基)丁酰基]吡咯-2-基}丁-1-醇或其药理学上可接受的盐，如盐酸盐。